Joel Eisner
Plus aucun poste en cours
Profil
Joel Eisner worked as an Associate Principal at Cato BioVentures, Head of Operations & Business Development Liaison at SanoGene Therapeutics, Inc., and Vice President of Clinical Operations at Innocrin Pharmaceuticals, Inc.
Anciens postes connus de Joel Eisner
| Sociétés | Poste | Fin |
|---|---|---|
Cato BioVentures
 Cato BioVentures Investment ManagersFinance Cato BioVentures (Cato BioVentures) is a venture capital subsidiary of Cato Research LLC founded in 1990 by Allen Cato and Lynda Sutton. The firm is headquartered in Durham, North Carolina. | Private Equity Investor | 31/12/2009 |
Innocrin Pharmaceuticals, Inc.
 Innocrin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Innocrin Pharmaceuticals, Inc. develops oral inhibitors for the treatment of castration-resistant prostate cancer. It develops small molecule CYP17 lyase-selective inhibitors to treat resistant hormonally-dependent breast and prostate cancers. The firm’s product under pipeline is VT-464, a dual mechanism lyase-selective CYP17 inhibitor and androgen receptor (AR) antagonist that disrupts the validated biochemical pathways required for prostate cancer growth androgen biosynthesis and AR transcriptional signaling. The company was founded in 2004 and is headquartered in Durham, NC. | Corporate Officer/Principal | - |
SanoGene Therapeutics, Inc.
 SanoGene Therapeutics, Inc. BiotechnologyHealth Technology SanoGene Therapeutics, Inc. operates as a biotechnology company. Its RNA interference (RNAi) technology to develop biopharmaceutical products for incurable cancers. The company was founded by Caralynn Nowinski Collens and Chirag Patel in 2006 and is headquartered in Chicago, IL. | Directeur des opérations | - |
Expériences
Fonctions occupées
Sociétés liées
| Entreprise privées | 3 |
|---|---|
Cato BioVentures
Cato BioVentures Investment ManagersFinance Cato BioVentures (Cato BioVentures) is a venture capital subsidiary of Cato Research LLC founded in 1990 by Allen Cato and Lynda Sutton. The firm is headquartered in Durham, North Carolina. | Finance |
SanoGene Therapeutics, Inc.
SanoGene Therapeutics, Inc. BiotechnologyHealth Technology SanoGene Therapeutics, Inc. operates as a biotechnology company. Its RNA interference (RNAi) technology to develop biopharmaceutical products for incurable cancers. The company was founded by Caralynn Nowinski Collens and Chirag Patel in 2006 and is headquartered in Chicago, IL. | Health Technology |
Innocrin Pharmaceuticals, Inc.
Innocrin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Innocrin Pharmaceuticals, Inc. develops oral inhibitors for the treatment of castration-resistant prostate cancer. It develops small molecule CYP17 lyase-selective inhibitors to treat resistant hormonally-dependent breast and prostate cancers. The firm’s product under pipeline is VT-464, a dual mechanism lyase-selective CYP17 inhibitor and androgen receptor (AR) antagonist that disrupts the validated biochemical pathways required for prostate cancer growth androgen biosynthesis and AR transcriptional signaling. The company was founded in 2004 and is headquartered in Durham, NC. | Health Technology |
